Lancet Diabetes & Endocrinology

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	1442
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	1034
South Africa to produce insulin for Africa in 2024	708
Reassessing driving safety in diabetes	664
Better testing and labelling of drugs for people with obesity	652
Anand Hardikar: a scientific nomad searching for the truth	342
What's preventing us from curbing the obesity crisis?	300
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	292
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study	265
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks	265
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	263
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	244
Implications of technology guidelines for low-income and middle-income countries	217
Artificial intelligence and diabetes: time for action and caution	209
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	207
World Health Assembly ratifies first global diabetes targets	197
Clinical features, investigation, and management of Addison's disease	196
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	186
A framework for improving diabetes care in humanitarian emergencies	181
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	168
Specific cortisol blockade in Cushing's syndrome	151
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	150
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	150
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	141
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	137

Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	134
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	126
What does renal failure teach us about our National Health System?	121
Challenging diabetes stigma starts and ends with all of us	121
Glycaemic index as part of the diabetes prevention strategy	119
Cardiovascular mortality trends among people with and without diabetes	117
Healthy weight for the next generation's health in China	117
The urgent need for a diabetes data rights charter	116
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	110
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	110
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	110
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48	108
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	104
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	103
Diabetes and mental health	103
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	101
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X	99
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England	98
Putting wellbeing at the core of diabetes care	97
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	95
Are we closer to surpassing residual renal risk in type 2 diabetes?	93
The role of nurses in diabetes care: challenges and opportunities	93
Bearing metabolism in mind: towards integrated care	91
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement	91
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	89
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	89
The promise and hope of GLP-1 receptor agonists	89
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	88
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	85
A roadmap for integrating mental health and diabetes services	85
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial	85
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	84
Understanding the mechanism of prediabetes remission in young people	79
CONCEPTT to care: the science of implementation in diabetes care	79
Diabetes: knowing your risk matters	78
Staging prediabetes and type 2 diabetes: the time to start is now	77
Male hypogonadism: pathogenesis, diagnosis, and management	76
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	76
Gender equality: timely and timeless	75
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	74
Improving HbA1c levels with advanced hybrid closed-loop therapy	72
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	70
Is it time to re-assess the development of thyroid function reference ranges?	70
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	68
Blood pressure control according to type 2 diabetes status	67
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	66
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	66
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	65
GLP-1 receptor agonists for obesity: eligibility across 99 countries	64
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	63

Glucagon, from past to present: a century of intensive research and controversies	63
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	62
Hypothalamic obesity: from basic mechanisms to clinical perspectives	62
The long and winding road to precision diabetology	62
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	61
Chronicling insulin from discovery to crisis	61
On the occasion of International Women's Day	61
Central diabetes insipidus from a patient's perspective	60
Embracing multiplicity in global diabetes estimation methods	58
Diagnosing diabetes in African populations: a twist in the tale	58
Sleep your way to better metabolic health	57
Vitamin D and fractures	56
USP8 genotype and tumour size as predictors for recurrence in Cushing's disease	56
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	56
Has the WHO Model Essential Medicines List lost its way?	55
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	55
World Autism Awareness Day: autism and metabolic health	55
Embracing community sport to promote global health	55
Teplizumab approval for type 1 diabetes in the USA	54
Is weight cycling clinically harmful?	53
Improving support for university students with type 1 diabetes	52
Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant	52
Screening type 1 diabetes and celiac disease by law	51
Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7	51
Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study	51
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	51
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	51
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	50
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	49
Automated insulin delivery postpartum: insights from the AiDAPT study extension	49
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	49
Insulin regimens during type 1 diabetes pregnancy	48
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	48
More options for young children with type 1 diabetes	47
Technology for type 1 diabetes: what impact will it have?	47
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?	47
Young adult-onset type 2 diabetes heralds a poor prognosis	46
Blood glucose targets in the critically ill: is one size fits all still appropriate?	46
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	46
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	46
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050	46
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	46
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study	46
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	45
MarÍa José Redondo: rethinking type 1 diabetes	45
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	45
An inclusive approach to people with disabilities in diabetes care and education	45
Disparities in fragility fracture and osteoporosis care in Africa	44
Addressing health and demographic challenges in Japan's ageing society	44
How clinically relevant is statin-induced diabetes?	43
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List	43
Causal inference in perinatal epidemiology: big data's false promises	43
From reproduction to metabolism: FSH as a key modulator in menopause	42
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	42
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	42
Impact of higher BMI on cardiometabolic risk: does height matter?	41
Rethinking prophylactic central neck dissection in clinically node-negative papillary thyroid cancer	40
Implications of microplastics as emerging endocrine disruptors	40
Diabetes and cancer in the age of multimorbidity	39
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	38
Life stage transitions for people with type 1 diabetes	38
Enhancing global access to diabetes medicines: policy lessons from the HIV response	38
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	36
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	36
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	36
ORION-3: delivering lipid lowering treatment for longer	36
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study	35
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	35
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	35
Redefining obesity: advancing care for better lives	35
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	35
Mendelian randomisation and vitamin D: the importance of model assumptions	34
Disease modifying therapies in diabetes and endocrinology	34
Iodine deficiency in Europe: vigilance and action required	33
What's in a decade?	33
Improving type 1 diabetes care globally: the importance of medical education	33
Correction to Lancet Diabetes Endocrinol 2026; 14: 317–26	32
From prominent corneal nerves to multiple endocrine neoplasia type 2B	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	32
Setmelanotide: new promise for the treatment of hypothalamic obesity?	31

Task shifting and task sharing in paediatric type 1 diabetes care: a global survey	31
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	31
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	31
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	31
High cost and poor availability of continuous glucose monitoring in low-income and middle-income countries	31
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	30
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	30
The growing global burden of thyroid cancer overdiagnosis	30
The potential role for artificial intelligence in fracture risk prediction	29
Incretins and the cardiovascular system: bridging digestion with metabolism	29
Maternal thyroid hypofunction and gestational diabetes risk	28
Sex differences in familial hypercholesterolaemia	28
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	28
Sleep: a neglected public health issue	28
Low visceral fat and kidney disease risk in men with diabetes	27
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	27
The double burden of poor diets	27
Heterogeneity in type 2 diabetes trajectories: informing public health approaches	27
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial	27
From survival to freedom: redefining success in type 1 diabetes	26
Correction to Lancet Diabetes & Endocrinology 2026; 14: 105–08	26
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	26
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	25
Energy drink ban: putting children's health first	25
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	25
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	25
From research to policy: still a long way to go	24
Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries	24
Bariatric surgery in children with obesity and type 2 diabetes	24
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	24
A global plastics treaty to protect endocrine health	24
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study	24
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial	24
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	23
Peripheral CB1 receptor blockade for treatment of obesity	23
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	23
More liberal use of bilateral adrenalectomy for bilateral adrenal tumours with cortisol excess	23
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	23
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	23
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	23
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	22
Addressing the educational needs of older adults with type 1 diabetes	22
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden	22
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	22
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	22
Correction to Lancet Diabetes Endocrinol 2026; 14: 259–74	22
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	21
Endocrine health in survivors of adult-onset cancer	21
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	21
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	20
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	20
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	20
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	20
What REDEFINE 5 signals for obesity trials in Asia and beyond	20
The voices of lived experience in diabetes and endocrinology	20
Does tirzepatide treatment improve skeletal muscle composition?	19
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	19
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	19
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	18
Out of touch medical care	18
3 months of romosozumab: a pragmatic clinical solution	18
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List	18
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	18